News

◄ Back

March 2, 2009, Weert, The Netherlands – Cambridge Major Laboratories and Novacta Biosystems (Welwyn Garden City, UK) have today announced a collaboration combining respective expertise in process development, custom synthesis and biocatalysis.

Novacta will develop biocatalytic approaches to target chiral intermediates which CML will then scale-up in facilities in Weert, the Netherlands.

“This collaboration illustrates the CML philosophy very well. CML is a strongly service-oriented business: adding more cutting-edge technology to our range of capabilities will broaden the solutions we are able to offer to our clients.” said Roger McDonald, European Business Development Director at Cambridge Major Laboratories. “Novacta Biosystems are recognized experts in their field, with a strong practical focus. CML is well-known for our pragmatic approach and problem-solving skills. Together we will be able to bring to bear a formidable range of chemistry tools. It is an exciting opportunity for CML and for our clients.”

“In CML we believe we have found the optimal partner to support commercial scale development of our world-class skills in biocatalysis. We feel there are many opportunities to develop more selective, cost-effective and greener solutions to API manufacture” commented Dr Georg Buchner, VP Corporate Development at Novacta. “We are both highly innovative companies, and working together we will be able to offer clients highly attractive and novel solutions to making key chiral molecules.”

Mike Dawson, CSO of Novacta commented:” We are delighted to work with CML as it complements ideally our offering in Biocatalysis. Novacta Biosystems, goal is to be the premier service provider of biocatalysis and metabolite solutions and an alliance with such a high profile company is a great step forward to offer our clients a complete service offering.”

Cambridge Major Laboratories is a leading global service-based chemistry outsourcing partner to the pharmaceutical and biotechnology industries, producing pharmaceutical intermediates, Active Pharmaceutical Ingredients, and other fine organic chemicals. The Company specializes in chemical process development and advanced multi-step organic synthesis, and operates from four facilities in the US and Europe. The Company has been FDA inspected and approved for cGMP manufacturing. Visit us at www.c-mlabs.com.

Novacta Biosystems is a unit of Novacta Ltd. that provides high value solutions to pharmaceutical, biotech, chemistry, agrochemical and biofuel companies. Based on the expertise of the scientific team, who originated from GSK’s Biotransformation and Natural product chemistry, Novacta developed a platform that harnesses the specificity and efficiency of biological systems, including biosynthetic pathway engineering, synthetic biology, biotransformation and metabolite factories. Each technology offers a flexible approach which can be tailored to meet the needs of the target application. Visit us at http://www.novactabio.com/biosystems.php

◄ Back